Medicine and Dentistry
Gamma Knife Radiosurgery
100%
Stereotactic Radiosurgery
79%
Neoplasm
73%
Radiosurgery
49%
Brain Metastasis
47%
Cavernous Hemangioma
28%
Cerebral Arteriovenous Malformation
28%
Radiation Therapy
24%
Metastatic Carcinoma
22%
Epidermal Growth Factor Receptor
22%
Bleeding
22%
Craniopharyngioma
19%
Neuroepithelioma
19%
Vestibular Schwannoma
19%
Dural Arteriovenous Fistula
19%
Meta-Analysis
19%
Lung Cancer
19%
Overall Survival
17%
Magnetic Resonance Imaging
15%
Tumor Progression
11%
Tyrosine-Kinase Inhibitor
11%
Progression Free Survival
10%
Intracranial Tumor
10%
Surgery
9%
Body Mass Index
9%
Vision
9%
Pediatrics
9%
Oligoastrocytoma
9%
Treatment of Non-Small Cell Lung Cancer
9%
Mature Teratoma
9%
Glossopharyngeal Neuralgia
9%
Macroadenoma
9%
Systematic Review
9%
Squamous Cell
9%
Lung
9%
Non-Small Cell Lung Cancer
9%
Retrospective Cohort Study
9%
Arm
9%
Survival Rate
8%
Radiation Response
8%
Adjuvant Therapy
7%
Cavernous Sinus
6%
Recurrent Disease
5%
Proportional Hazards Model
5%
Retrospective Study
5%
Karnofsky Performance Status
5%
Neuroscience
Arteriovenous Malformation
38%
Epidermal Growth Factor Receptor
31%
Radiation Therapy
28%
Parenchyma
25%
Magnetic Resonance Imaging
25%
Tyrosine Kinase Inhibitor
20%
Cavernous Sinus
20%
Magnetic Resonance Imaging
15%
Peripheral Neuropathy
12%
Brain Cancer
11%
Astrocytoma
9%
Body Mass Index
9%
Meningioma
9%
Acromegaly
9%
Occipital Neuralgia
9%
Craniopharyngioma
9%
Machine Learning Algorithm
9%
Ependymoma
9%
Optic Nerve
9%
Visual Field Defect
9%
Meta-Analysis
9%
Intracranial Tumor
9%
Leukoencephalopathy
9%
Adverse Effect
9%
Immunotherapy
9%
Radiation Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
56%
Brain Metastasis
47%
Epidermal Growth Factor Receptor
31%
Overall Survival
21%
Protein Tyrosine Kinase Inhibitor
20%
Bleeding
20%
Non Small Cell Lung Cancer
19%
Neuroepithelioma
19%
Brain Arteriovenous Malformation
19%
Intracranial Tumor
11%
Cohort Study
11%
Metastasis
9%
Acromegaly
9%
Lung Cancer
9%
Remission
9%
Ependymoma
9%
Cavernous Hemangioma
9%
Meningioma
9%
Progression Free Survival
7%
Survival Rate
6%
Squamous Cell Lung Carcinoma
5%
Immunotherapy
5%